1. Home
  2. > Healthcare Market Trends
Benign Prostatic Hyperplasic Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Procedure Type, and End User, and Geography

Benign Prostatic Hyperplasic Devices Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product, Procedure Type, and End User, and Geography

  • July 2022
  • 190 pages
  • ID: 6316359
  • Format: PDF
  • The Insight Partners


Table of Contents

Search Inside

The global benign prostatic hyperplasic devices market is expected to US$ 2,078.78 million in 2021 to US$ 3,467.31 million by 2028; it is expected to grow with a CAGR of 7.6% from 2022 to 2028.

An increase in the prevalence of benign prostatic hyperplasia along with growing risk factors and a rise in investments, funds, and grants for research in BPH treatment boost the global benign prostatic hyperplasic devices market growth.

Benign prostatic hyperplasia (BPH) is a prostate enlargement caused by excessive cell growth in the prostate.BPH is a benign (non-cancerous) prostate condition.

Non-cancerous conditions are not usually fatal and do not spread (metastasize) to other body parts.BPH doesn’t raise the risk of prostate cancer; unless it manifests symptoms, BPH isn’t considered a health issue.

Almost all men will have some prostate growth by the age of 70. Getting older, having more belly fat (also known as abdominal obesity), and not getting enough exercise to raise the risk of developing BPH.

Players operating in the benign prostatic hyperplasic devices industry focus on investing high amounts in the development of advanced surgical technologies as alternatives to conventional techniques. Advanced devices enabled with new technologies help provide immediate relief and reduce morbidity.

• In January 2022, ProVerum, a start-up supported by EIT Health, received US$ 31.22 million in Series A funding from Gilde Healthcare, Lightstone Ventures, and Atlantic Bridge. ProVerum, an Irish company, has developed ProVee, a cutting-edge treatment solution for men with symptomatic BPH. The company aims to market its innovative device in the US and Europe with the help of recent funding.

• In June 2021, Zenflow, Inc., a medical device company developing a minimally invasive treatment for urinary obstruction caused by BPH or enlarged prostate, declared the completion of its Series B funding round with a total of US$ 24 million. The investment was led by Invus Opportunities and included participation from Medical Technology Venture Partners, F-Prime Capital, CloudStone Capital, Astia Angels, Golden Seeds, SV Tech Ventures, etc.

• In June 2021, Procept Biorobotics raised US$ 85 million to commercialize the AquaBeam system as a global BPH treatment. With this product, the company intends to make an impact with its water-based robotic technology in the field of prostate surgery. The series G financing was led by Fidelity Management & Research Company, with additional backing from T. Rowe Price Associates, CPMG, Perceptive Advisors, Viking Global Investors, and Duquesne Family Office.
• In July 2019, Medeon Biodesign, Inc, a publicly traded Taiwan medical device company, announced that it recently led and closed an investment in Prodeon. Prodeon is a Taiwan-based company offering a simple, office-based treatment option for patients who need quick relief from LUTS caused due to BPH.
• In April 2018, ProVerum Medical closed a US$ 4.2 million seed investment, with Atlantic Bridge University Fund leading the investment round. With this investment, the company aims to commence its first human trials of its product for BPH treatment. This product includes a nitinol implant to dilate the prostatic urethra without altering the structure of the prostate anatomy. The nitinol implant can be manufactured to a small size to simplify the process of implantation through a 10–15-minute long minimally invasive surgery.
• In February 2018, Zenflow, a medical device company based in San Francisco, California, announced a US$ 31.4 million Series A investment round for further advancements in its minimally invasive technique for treating BPH or an enlarged prostate.

Product-Based Insights
Based on the product, the benign prostatic hyperplasic devices market is segmented into resectoscopes, radiofrequency ablation devices, urology lasers, prostatic stents, and implants.The resectoscopes segment is likely to hold the largest market share in 2022.

However, the urology lasers segment is anticipated to register the highest CAGR during the forecast period due to the high demand by physicians and the rising initiatives of market players in the launch and product expansion.

Procedure Type Insights
Based on procedure type, the benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others.In 2022, the transurethral resection of the prostate segment is likely to hold the market’s largest share.

Furthermore, the same segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028, owing to its visual, hands-on access to the prostate, ability to the immediate removal of excess tissue, the ability of transurethral resection of the prostate (TURP) to combine with other procedures.

End User-Based Insights
Based on end user, the benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others.In 2022, the hospitals segment is likely to hold the largest share of the market.

Moreover, the clinics segment is expected to witness growth in its demand at the fastest CAGR from 2022 to 2028, owing to an increase in the number of clinics at a lower cost for treatment, easy accessibility, and flexibility with the short waiting time.
National Center for Biotechnology Information (NCBI), National Library of Medicine, Indiana University School of Medicine, Centers for Disease Control and Prevention (CDC), Canadian Risk Factor Atlas (CRFA), World Bank, Urology Foundation, International Diabetes Federation (IDF), National Statistics Institute (INE), National Medica Device Promotion Council, International Trade Administration, Department of Emergency Medicine are among the primary and secondary sources referred to while preparing the report on the benign prostatic hyperplasic devices market.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

ReportLinker may already be registered as a supplier with your company. If you want to Order by PO, check with us first and we'll let you know if we are a registered supplier and what the vendor number is. Otherwise, we'll provide you with the necessary information to register ReportLinker as a vendor.

Grace helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at [email protected] to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - [email protected] or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers

Middle East & Africa Benign Prostatic Hyperplasic Devices Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Product, Procedure Type, and End User

  • $ 3000
  • October 2022
  • 126 pages

The benign prostatic hyperplasic devices market in the Middle East & Africa is expected to grow from US$ 91.28 million in 2022 to US$ 130.44 million by 2028; it is estimated to grow at a CAGR of 6.1% from ...

  • Middle East
  • Africa
  • Healthcare
  • Genitourinary System Disease
  • Industry analysis
  • Overweight Prevalence
  • Health Expenditure

Consumer Health in Paraguay $ 2650 September 2022


Reportlinker.com © Copyright 2022. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on